AlkermesvsJohnson & Johnson

ALKS and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

Alkermes (ALKS) has a market value of $7.8B and Johnson & Johnson (JNJ) $689B. Over the last year, with dividends, ALKS moved +49.7% and JNJ +50.3%. Dividend yield: ALKS none, JNJ 1.85%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ALKS$7.8B

    JNJ$689B

    JNJ is 88 times ALKS

  • Revenue, 12 months

    ALKS$1.8B

    JNJ$99.3B

    JNJ is 57 times ALKS

  • Net income, 12 months

    ALKS-$351.0K

    JNJ$16.1B

  • Operating margin

    ALKS3.7%

    JNJ–

  • ROIC

    ALKS1.8%

    JNJ12.4%

    10.6 points apart

  • P/E

    ALKS–

    JNJ42.8

  • Dividend yield

    ALKS0.0%

    JNJ1.8%

    1.9 points apart

  • 5-year return

    ALKS+96.1%

    JNJ+99.1%

    3.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ALKS+96.1%

JNJ+99.1%

10015020020222023202420252026
Returns by period
PeriodALKSWith dividendsJNJWith dividends
1 year since November 12, 2025+49.7%Price +49.7%+50.3%Price +47.0%
3 years since November 13, 2023+96.1%+25.2% a yearPrice +96.1%+110.8%+28.2% a yearPrice +93.6%
5 years since November 12, 2021+96.1%+14.4% a yearPrice +96.1%+99.1%+14.8% a yearPrice +73.2%
10 years since November 15, 2016-20.8%-2.3% a yearPrice -20.8%+222.3%+12.4% a yearPrice +145.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ALKSAlkermesJNJJohnson & Johnson

Valuation

ALKSJNJ
Valuation
Price$47.03$285.75
Market value$7.8B$689B
Enterprise value (EV)$8.6B$716B
P/E–42.8
P/E, 5-year median13.321.9
P/B4.28.5
EV/EBIT133.640.4
Free cash flow yield2.9%3.0%

Results and growth

ALKSJNJ
Results and growth
Revenue, 12 months$1.8B$99.3B
Net income, 12 months-$351.0K$16.1B
Free cash flow, 12 months$227M$20.6B
Earnings per share, 12 months-$0.02$6.59
Revenue growth, year on year-5.3%6.1%
Revenue growth a year, past+7.3%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ALKSJNJ
Margins and returns on capital
Gross margin82.9%67.6%
Operating margin3.7%–
Net margin-0.0%16.2%
ROIC1.8%12.4%
ROE-0.0%19.7%

Balance sheet

ALKSJNJ
Balance sheet
Cash$755M$17.2B
Total debt$1.6B$44.7B
Net debt / EBITDA8.11.1
Interest cover0.7×18.0×

Dividends and buybacks

ALKSJNJ
Dividends and buybacks
Dividend yield–1.8%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ALKS or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Alkermes or Johnson & Johnson?

By market value, Johnson & Johnson ($689B) is about 87.9 times Alkermes ($7.8B), at today's prices.

How did ALKS and JNJ stock do over the last 10 years?

Since November 15, 2016, ALKS's price moved -20.8% and JNJ's +145.7%. With dividends: ALKS -20.8% (-2.3% a year), JNJ +222.3% (+12.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ALKS or JNJ?

The dividend yield at today's price is none for Alkermes and 1.85% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Alkermes or Johnson & Johnson?

Over the last twelve months, the net margin was -0.0% for Alkermes and 16.2% for Johnson & Johnson, and the operating margin 3.7% and –. Revenue was $1.8B and $99.3B.

Which is the better investment, Alkermes or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.